Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease

Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68Ga-DOTATATE PET/CT

ABSTRACT

An 8-year-old girl with refractory high-risk neuroblastoma underwent 68Ga-DOTATATE PET/CT to evaluate the feasibility of potential 177Lu-DOTATATE therapy. The scan showed multiple foci of abnormal 68Ga-DOTATATE accumulation in the bone region, indicating the presence of bone metastases. Unexpectedly, an abnormal tracer uptake was noted in the left lateral ventricle area. The contrast-enhanced brain MRI showed obvious enhancement of this lesion, suggesting the diagnosis of choroid plexus metastasis. Our case shows that 68Ga-DOTATATE PET/CT might be useful in diagnosing choroid plexus metastasis.

Current clinical application of lutetium‑177 in solid tumors (Review)

Radionuclide-based therapy represents a novel treatment regimen for tumors. Among these therapies, lutetium-177 (177Lu) has gained significant attention due to its stability and safety, as well as its ability to emit both γ and β rays, allowing for both imaging with single photon emission computed tomography and tumor treatment. As a result, 177Lu can be used for both diagnosis and treatment for diseases such as prostatic and gastric cancer. Therefore, based on the available data, the present review provides a brief overview of the clinical applications of 177Lu-targeted radionuclide therapy in metastatic prostate cancer, neuroendocrine tumors and other types of solid tumors, and highlights the current therapeutic effect, reduction in damage to normal tissues and future research directions, including the development of new nuclides and the application of more nuclides in different tumors. In the future, such treatments could be used in more tumors.